Theratechnologies Inc.

Angiochem Inc.

Transfert Plus

Jonathan Michaud-Levesque

Michel Demeule

Richard Béliveau

Krishna G Peri

Abdelkrim Habi

Richard Beliveau

Nathalie Bousquet-Gagnon

Stephane Barakat

Yanick Bertrand

Yannève Rolland

Julie Jodoin

Peptide compounds derived from human melanotransferrin, and compositions thereof, are described. Uses of these peptide compounds, for example to modulate angiogenesis and/or cell migration, and/or to treat angiogenesis-related disorders (e.g., cancer), are also described.

Peptide compounds derived from melanotransferrin and uses thereof

The present invention is directed to polypeptides (e.g., fragments) derived from P-glycoprotein and caveolin-1 which are capable of inhibiting the interaction between these two proteins. Inhibition of this interaction leads to increase of efflux of compounds that are transported by P-gp. The invention further includes methods of treating patients having diseases that benefit from increased P-gp-mediated efflux. Such diseases include neoplasms such as cancer and neurological diseases such as neurodegenerative diseases.

Compounds for stimulating P-glycoprotein function and uses thereof

The invention relates to novel regulators of plasminogen activation and their use for regulating cell migration, plasminolysis, angiogenesis, fibrinolysis, for treating cancer and thrombo-embolic diseases such as heart stroke. Furthermore, the present invention relates to novel pharmaceutical compositions form regulating cell migration, plasminolysis, angiogenesis and for treating cancer. In particular, the present invention relates to a method of regulating the activation of plasminogen comprising contacting a solution of pro-urokinase (uPA) or tissue plasminogen activator (tPA) and plasminogen with melanotransferrin (p97) for a time sufficient to effect regulation thereof.

Compound and method for regulating plasminogen activation and cell migration

Growing community of inventors

Montreal, Canada

Jonathan Michaud-Levesque